Robert G. Holloway
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Robert G. Holloway has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
Adam G. Kelly
From the Department of Neurology, University of Rochester Medical Center, NY (B.P.G., A.G.K., R.G.H.); College of Arts and Science, University of Rochester, NY (G.P.A.); and Department of Neurology, Division of Neurocritical Care and Emergency Neurology, Yale School of Medicine, New Haven, CT (D.Y.H.).
3 shared publicationsAdam Kelly
Department of Neurology, Division of Palliative Care, University of Rochester Medical Center, Rochester, New York
2 shared publicationsBenjamin P. George
From the Department of Neurology, University of Rochester Medical Center, NY (B.P.G., A.G.K., R.G.H.); College of Arts and Science, University of Rochester, NY (G.P.A.); and Department of Neurology, Division of Neurocritical Care and Emergency Neurology, Yale School of Medicine, New Haven, CT (D.Y.H.).
2 shared publicationsCurtis Benesch
From the Department of Neurology (A.K., C.B., R.G.H., J.P.T.) and the Office of Clinical Practice Evaluation (R.G.H., D.T.), University of Rochester, Rochester, NY
2 shared publicationsDeborah Tuttle
From the Department of Neurology (A.K., C.B., R.G.H., J.P.T.) and the Office of Clinical Practice Evaluation (R.G.H., D.T.), University of Rochester, Rochester, NY
2 shared publications- Manish N. Shah
BerbeeWalsh Department of Emergency Medicine University of Wisconsin‐Madison Madison Wisconsin USA
2 shared publications
Latest Publications
- Open Access
- 11 August 2022
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 8 (5) , e200008
A Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease
Background and Objectives To recruit and characterize a national cohort of individuals who have a genetic variant (LRRK2 G2019S) that increases risk of Parkinson disease (PD), assess participant satisfaction with a decentralized, remote research model, and evaluate interest in future clinical trials. Methods In partnership with 23andMe, Inc., a personal genetics company, LRRK2 G2019S carriers with and without PD were recruited to participate in an ongoing 36-month decentralized, remote natural history study. We examined concordance between self-reported and clinician-determined PD diagnosis. We applied the Movement Disorder Society Prodromal Parkinson9s Disease Criteria and asked investigators to identify concern for parkinsonism to distinguish participants with probable prodromal PD. We compared baseline characteristics of LRRK2 G2019S carriers with PD, with prodromal PD, and without PD. Results Over 15 months, we enrolled 277 LRRK2 G2019S carriers from 34 states. At baseline, 60 had self-reported PD (mean [SD] age 67.8 years [8.4], 98% White, 52% female, 80% Ashkenazi Jewish, and 67% with a family history of PD), and 217 did not (mean [SD] age 53.7 years [15.1], 95% White, 59% female, 73% Ashkenazi Jewish, and 57% with a family history of PD). Agreement between self-reported and clinician-determined PD status was excellent (κ = 0.94, 95% confidence interval 0.89–0.99). Twenty-four participants had prodromal PD; 9 met criteria for probable prodromal PD and investigators identified concern for parkinsonism in 20 cases. Compared with those without prodromal PD, participants with prodromal PD were older (63.9 years [9.0] vs 51.9 years [15.1], p < 0.001), had higher modified Movement Disorders Society-Unified Parkinson9s Disease Rating Scale motor scores (5.7 [4.3] vs 0.8 [2.1], p < 0.001), and had higher Scale for Outcomes in PD for Autonomic Symptoms scores (11.5 [6.2] vs 6.9 [5.7], p = 0.002). Two-thirds of participants enrolled were new to research, 97% were satisfied with the overall study, and 94% of those without PD would participate in future preventive clinical trials. Discussion An entirely remote national cohort of LRRK2 G2019S carriers was recruited from a single site. This study will prospectively characterize a large LRRK2 G2019S cohort, refine a new model of clinical research, and engage new research participants willing to participate in future therapeutic trials.
- 11 August 2022
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 8 (5) , e200008
Open AccessA Remote Longitudinal Observational Study of Individuals at Genetic Risk for Parkinson Disease
Background and Objectives To recruit and characterize a national cohort of individuals who have a genetic variant (LRRK2 G2019S) that increases risk of Parkinson disease (PD), assess participant satisfaction with a decentralized, remote research model, and evaluate interest in future clinical trials. Methods In partnership with 23andMe, Inc., a personal genetics company, LRRK2 G2019S carriers with and without PD were recruited to participate in an ongoing 36-month decentralized, remote natural history study. We examined concordance between self-reported and clinician-determined PD diagnosis. We applied the Movement Disorder Society Prodromal Parkinson9s Disease Criteria and asked investigators to identify concern for parkinsonism to distinguish participants with probable prodromal PD. We compared baseline characteristics of LRRK2 G2019S carriers with PD, with prodromal PD, and without PD. Results Over 15 months, we enrolled 277 LRRK2 G2019S carriers from 34 states. At baseline, 60 had self-reported PD (mean [SD] age 67.8 years [8.4], 98% White, 52% female, 80% Ashkenazi Jewish, and 67% with a family history of PD), and 217 did not (mean [SD] age 53.7 years [15.1], 95% White, 59% female, 73% Ashkenazi Jewish, and 57% with a family history of PD). Agreement between self-reported and clinician-determined PD status was excellent (κ = 0.94, 95% confidence interval 0.89–0.99). Twenty-four participants had prodromal PD; 9 met criteria for probable prodromal PD and investigators identified concern for parkinsonism in 20 cases. Compared with those without prodromal PD, participants with prodromal PD were older (63.9 years [9.0] vs 51.9 years [15.1], p < 0.001), had higher modified Movement Disorders Society-Unified Parkinson9s Disease Rating Scale motor scores (5.7 [4.3] vs 0.8 [2.1], p < 0.001), and had higher Scale for Outcomes in PD for Autonomic Symptoms scores (11.5 [6.2] vs 6.9 [5.7], p = 0.002). Two-thirds of participants enrolled were new to research, 97% were satisfied with the overall study, and 94% of those without PD would participate in future preventive clinical trials. Discussion An entirely remote national cohort of LRRK2 G2019S carriers was recruited from a single site. This study will prospectively characterize a large LRRK2 G2019S cohort, refine a new model of clinical research, and engage new research participants willing to participate in future therapeutic trials.
- 1 June 2017
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 7 (3) , 191-193
The emerging partnership between palliative care and stroke
Stroke care displays 2 truisms. First, a severe stroke is a common event often close to one's death. It unleashes a series of intense conversations among clinicians, patients, and families, rife with uncertainty, about health states with varying degrees of acceptability and what makes life worth living.1 Second, enormous variations in clinical practice remain prevalent, including end-of-life care practices. This end-of-life practice variation has been called a hidden curriculum, providing medical students with insights into how the location of their residency training helps shape the type of physicians they will become.2 It is surprising, therefore, how little we know about these important life transitions in our patients with stroke. But this ignorance is beginning to change.
- 1 June 2017
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 7 (3) , 191-193
The emerging partnership between palliative care and stroke
Stroke care displays 2 truisms. First, a severe stroke is a common event often close to one's death. It unleashes a series of intense conversations among clinicians, patients, and families, rife with uncertainty, about health states with varying degrees of acceptability and what makes life worth living.1 Second, enormous variations in clinical practice remain prevalent, including end-of-life care practices. This end-of-life practice variation has been called a hidden curriculum, providing medical students with insights into how the location of their residency training helps shape the type of physicians they will become.2 It is surprising, therefore, how little we know about these important life transitions in our patients with stroke. But this ignorance is beginning to change.
- 1 February 2017
- Published by Wolters Kluwer Health in Stroke
- Vol. 48 (2) , 420-427
Timing of Percutaneous Endoscopic Gastrostomy for Acute Ischemic Stroke
Background and Purpose—Stroke guidelines recommend time-limited trials of nasogastric feeding prior to percutaneous endoscopic gastrostomy (PEG) tube placement. We sought to describe timing of PEG placement and identify factors associated with early PEG for acute ischemic stroke. Methods—We designed a retrospective observational study to examine time to PEG for ischemic stroke admissions in the Nationwide Inpatient Sample, 2001 to 2011. We defined early PEG placement as 1 to 7 days from admission. Using multivariable regression analysis, we identified the effects of patient and hospital characteristics on PEG timing. Results—We identified 34 623 admissions receiving a PEG from 2001 to 2011, 53% of which received the PEG 1 to 7 days from admission. Among hospitals placing ≥10 PEG tubes, median time to PEG for individual hospitals ranged from 3 days to over 3 weeks (interquartile range 6–8.5 days). Older adult age groups were associated with early PEG (≥85 years versus 18–54 years: adjusted odds ratio 1.68, 95% confidence interval 1.50–1.87). Those receiving a PEG and tracheostomy were more likely to receive the PEG beyond 7 days, and these patients were more often younger compared with PEG only recipients. Those admitted to high-volume hospitals were more likely to receive their PEG early (≥350 versus Conclusions—More than half of the PEG recipients received their surgical feeding tube within 7 days of admission. The oldest old, who may benefit most from time-limited trials of nasogastric feeding for ≥2 to 3 weeks, were most likely to receive a PEG within 7 days.
- 1 February 2017
- Published by Wolters Kluwer Health in Stroke
- Vol. 48 (2) , 420-427
Timing of Percutaneous Endoscopic Gastrostomy for Acute Ischemic Stroke
Background and Purpose—Stroke guidelines recommend time-limited trials of nasogastric feeding prior to percutaneous endoscopic gastrostomy (PEG) tube placement. We sought to describe timing of PEG placement and identify factors associated with early PEG for acute ischemic stroke. Methods—We designed a retrospective observational study to examine time to PEG for ischemic stroke admissions in the Nationwide Inpatient Sample, 2001 to 2011. We defined early PEG placement as 1 to 7 days from admission. Using multivariable regression analysis, we identified the effects of patient and hospital characteristics on PEG timing. Results—We identified 34 623 admissions receiving a PEG from 2001 to 2011, 53% of which received the PEG 1 to 7 days from admission. Among hospitals placing ≥10 PEG tubes, median time to PEG for individual hospitals ranged from 3 days to over 3 weeks (interquartile range 6–8.5 days). Older adult age groups were associated with early PEG (≥85 years versus 18–54 years: adjusted odds ratio 1.68, 95% confidence interval 1.50–1.87). Those receiving a PEG and tracheostomy were more likely to receive the PEG beyond 7 days, and these patients were more often younger compared with PEG only recipients. Those admitted to high-volume hospitals were more likely to receive their PEG early (≥350 versus Conclusions—More than half of the PEG recipients received their surgical feeding tube within 7 days of admission. The oldest old, who may benefit most from time-limited trials of nasogastric feeding for ≥2 to 3 weeks, were most likely to receive a PEG within 7 days.
- 12 August 2015
- Published by Springer Nature
- p. 1025-1030
Neurotrauma, Death by Neurological Criteria
- 2 September 2014
- Published by Wolters Kluwer Health in Neurology
- Vol. 83 (10) , 874-882
Current practices in feeding tube placement for US acute ischemic stroke inpatients
Objective: We sought to identify current US hospital practices for feeding tube placement in ischemic stroke. Methods: In a retrospective observational study, we examined the frequency of feeding tube placement among hospitals in the Nationwide Inpatient Sample with ≥30 adult ischemic stroke admissions annually with length of stay greater than 3 days. We examined trends from 2004 to 2011 and predictors using data from more recent years (2008–2011). We used multilevel multivariable regression models accounting for a hospital random effect, adjusted for patient-level and hospital-level factors to predict feeding tube placement. Results: Feeding tube insertion rates did not change from 2004 to 2011 (8.1 vs 8.4 per 100 admissions; p trend = 0.11). Among 1,540 hospitals with 164,408 stroke hospitalizations from 2008 to 2011, a feeding tube was placed 8.8% of the time (n = 14,480). Variation in the rate of feeding tube placement was high, from 0% to 26% between hospitals (interquartile range 4.8%–11.2%). In the subset with available race/ethnicity data (n = 88,385), after controlling for patient demographics, socioeconomics, and comorbidities, hospital factors associated with feeding tube placement included stroke volume (odds ratio [OR] 1.28 highest vs lowest quartile; 95% confidence interval [CI] 1.10–1.49), for-profit status (OR 1.13 vs nonprofit; 95% CI 1.01–1.25), and intubation use (OR 1.66 highest vs lowest quartile; 95% CI 1.47–1.87). In addition, hospitals with higher rates of black/Hispanic stroke admissions had increased risk of feeding tube placement (OR 1.28 highest vs lowest quartile; 95% CI 1.14–1.44). Conclusions: Variation in feeding tube insertion rates across hospitals is large. Differences across hospitals may be partly explained by external factors beyond the patient-centered decision to insert a feeding tube.
- 2 September 2014
- Published by Wolters Kluwer Health in Neurology
- Vol. 83 (10) , 874-882
Current practices in feeding tube placement for US acute ischemic stroke inpatients
Objective: We sought to identify current US hospital practices for feeding tube placement in ischemic stroke. Methods: In a retrospective observational study, we examined the frequency of feeding tube placement among hospitals in the Nationwide Inpatient Sample with ≥30 adult ischemic stroke admissions annually with length of stay greater than 3 days. We examined trends from 2004 to 2011 and predictors using data from more recent years (2008–2011). We used multilevel multivariable regression models accounting for a hospital random effect, adjusted for patient-level and hospital-level factors to predict feeding tube placement. Results: Feeding tube insertion rates did not change from 2004 to 2011 (8.1 vs 8.4 per 100 admissions; p trend = 0.11). Among 1,540 hospitals with 164,408 stroke hospitalizations from 2008 to 2011, a feeding tube was placed 8.8% of the time (n = 14,480). Variation in the rate of feeding tube placement was high, from 0% to 26% between hospitals (interquartile range 4.8%–11.2%). In the subset with available race/ethnicity data (n = 88,385), after controlling for patient demographics, socioeconomics, and comorbidities, hospital factors associated with feeding tube placement included stroke volume (odds ratio [OR] 1.28 highest vs lowest quartile; 95% confidence interval [CI] 1.10–1.49), for-profit status (OR 1.13 vs nonprofit; 95% CI 1.01–1.25), and intubation use (OR 1.66 highest vs lowest quartile; 95% CI 1.47–1.87). In addition, hospitals with higher rates of black/Hispanic stroke admissions had increased risk of feeding tube placement (OR 1.28 highest vs lowest quartile; 95% CI 1.14–1.44). Conclusions: Variation in feeding tube insertion rates across hospitals is large. Differences across hospitals may be partly explained by external factors beyond the patient-centered decision to insert a feeding tube.
- 1 February 2014
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 27 (1) , 61-65
Ethical considerations in stroke patients
Medical decision-making in stroke patients can be complex and often involves ethical challenges, from the perspective of healthcare providers as well as patients and their families. Awareness of these challenges and knowledge of current ethical topics in stroke may improve the quality of care provided to stroke patients. Predictive scores are increasingly available to estimate prognosis following stroke, though their usefulness in decision-making for individual patients remains unclear. Medical decisions requiring a surrogate decision-maker can be challenging; surrogates may also be susceptible to systematic biases in their decision-making. Variations in care are common and possibly related to under-utilization or over-utilization of resources. However, patient preferences may explain some of the variability as well. Early mortality may be related to patient and family preferences regarding life-sustaining measures rather than the provision of care that is not well tolerated or evidence-based. Ethical challenges are common in the care of stroke patients. An effective understanding of these topics is essential for clinicians to deliver patient-centered, preference-sensitive care.
- 1 February 2014
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 27 (1) , 61-65
Ethical considerations in stroke patients
Medical decision-making in stroke patients can be complex and often involves ethical challenges, from the perspective of healthcare providers as well as patients and their families. Awareness of these challenges and knowledge of current ethical topics in stroke may improve the quality of care provided to stroke patients. Predictive scores are increasingly available to estimate prognosis following stroke, though their usefulness in decision-making for individual patients remains unclear. Medical decisions requiring a surrogate decision-maker can be challenging; surrogates may also be susceptible to systematic biases in their decision-making. Variations in care are common and possibly related to under-utilization or over-utilization of resources. However, patient preferences may explain some of the variability as well. Early mortality may be related to patient and family preferences regarding life-sustaining measures rather than the provision of care that is not well tolerated or evidence-based. Ethical challenges are common in the care of stroke patients. An effective understanding of these topics is essential for clinicians to deliver patient-centered, preference-sensitive care.
- 19 February 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (8) , 764-772
Estimating and communicating prognosis in advanced neurologic disease
Prognosis can no longer be relegated behind diagnosis and therapy in high-quality neurologic care. High-stakes decisions that patients (or their surrogates) make often rest upon perceptions and beliefs about prognosis, many of which are poorly informed. The new science of prognostication—the estimating and communication “what to expect”—is in its infancy and the evidence base to support “best practices” is lacking. We propose a framework for formulating a prediction and communicating “what to expect” with patients, families, and surrogates in the context of common neurologic illnesses. Because neurologic disease affects function as much as survival, we specifically address 2 important prognostic questions: “How long?” and “How well?” We provide a summary of prognostic information and highlight key points when tailoring a prognosis for common neurologic diseases. We discuss the challenges of managing prognostic uncertainty, balancing hope and realism, and ways to effectively engage surrogate decision-makers. We also describe what is known about the nocebo effects and the self-fulfilling prophecy when communicating prognoses. There is an urgent need to establish research and educational priorities to build a credible evidence base to support best practices, improve communication skills, and optimize decision-making. Confronting the challenges of prognosis is necessary to fulfill the promise of delivering high-quality, patient-centered care.
- 19 February 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (8) , 764-772
Estimating and communicating prognosis in advanced neurologic disease
Prognosis can no longer be relegated behind diagnosis and therapy in high-quality neurologic care. High-stakes decisions that patients (or their surrogates) make often rest upon perceptions and beliefs about prognosis, many of which are poorly informed. The new science of prognostication—the estimating and communication “what to expect”—is in its infancy and the evidence base to support “best practices” is lacking. We propose a framework for formulating a prediction and communicating “what to expect” with patients, families, and surrogates in the context of common neurologic illnesses. Because neurologic disease affects function as much as survival, we specifically address 2 important prognostic questions: “How long?” and “How well?” We provide a summary of prognostic information and highlight key points when tailoring a prognosis for common neurologic diseases. We discuss the challenges of managing prognostic uncertainty, balancing hope and realism, and ways to effectively engage surrogate decision-makers. We also describe what is known about the nocebo effects and the self-fulfilling prophecy when communicating prognoses. There is an urgent need to establish research and educational priorities to build a credible evidence base to support best practices, improve communication skills, and optimize decision-making. Confronting the challenges of prognosis is necessary to fulfill the promise of delivering high-quality, patient-centered care.
- 1 September 2012
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 67 (9) , 541-543
Evidence, Preferences, Recommendations—Finding the Right Balance in Patient Care
The authors of this report use a clinical case to highlight the difficulties of integrating patient preferences in making decisions in medical care based on evidence-based medicine. As an increasing number of evidence-based performance measures are used to monitor care, there has been growing awareness that patient preferences should play a major part in medical decisions. It has been suggested that some physicians, in the interest of patient autonomy, tend to place too much of the burden of medical decision-making responsibilities on patients. Although it is clear that patients’ preferences and values should not be the sole drivers of clinical decisions, it is also increasingly clear that wide gaps remain in the practice of shared decision making. The case involved a 75-year-old man with congestive heart failure with repeated admissions to a hospital. Because he was not a candidate for a heart transplant, his cardiologist recommended a destination ventricular assist device (VAD). The patient was ambivalent about trying the VAD. Progress has been made in incorporating patient preferences in medical decision making, but much more work is needed. To this end, the authors have developed a 5-step framework for incorporating the best features of an evidence-based and preference-based approach. The first step in practicing preference-based medicine is to have an effective meeting of the patient, family members, and appropriate members of the treatment team. Clinicians must carefully clarify the medical evidence concerning benefits and burdens of future treatment. The second step involves sharing information and expertise with the patient and family. The treating physicians should explain treatment options and prognosis with and without the treatment while learning about the patient’s values, priorities, and expectations in light of the medical facts. Patient preferences may be broad in that some may lean toward aggressive interventions to prolong life and others toward naturalism. The third step is to critically evaluate the evidence and identify physician and patient biases that might influence decision making. Unrealistic overly optimistic expectations of prolonged life or acceptance of the likelihood of death have a major impact in patient preferences. The fourth step involves integration of the information from the evidence-based and preference-based approaches and making a recommendation on future care. In the case of the patient with end-stage congenital heart defect, the treating cardiologist evaluated the benefits of a VAD in light of patient and family expectations, goals, and clear understanding of the likely outcome with and without VAD insertion. With input from the VAD and palliative care teams, the cardiologist recommended against a VAD. After discharge to home hospice, the patient continued his heart-failure treatments, hoping to live as well and as long as he could without further invasive interventions. In the fifth step, physician performance is evaluated. All aspects of the decision-making process are examined to ensure that the recommendation of the clinicians incorporated the preferences of patients and families. This case demonstrates that medical decisions regarding future care that allow patients to get the most out of medical interventions are those that integrate the preferences of informed patients and families who understand the clinical implications of the decision.
- 1 September 2012
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 67 (9) , 541-543
Evidence, Preferences, Recommendations—Finding the Right Balance in Patient Care
The authors of this report use a clinical case to highlight the difficulties of integrating patient preferences in making decisions in medical care based on evidence-based medicine. As an increasing number of evidence-based performance measures are used to monitor care, there has been growing awareness that patient preferences should play a major part in medical decisions. It has been suggested that some physicians, in the interest of patient autonomy, tend to place too much of the burden of medical decision-making responsibilities on patients. Although it is clear that patients’ preferences and values should not be the sole drivers of clinical decisions, it is also increasingly clear that wide gaps remain in the practice of shared decision making. The case involved a 75-year-old man with congestive heart failure with repeated admissions to a hospital. Because he was not a candidate for a heart transplant, his cardiologist recommended a destination ventricular assist device (VAD). The patient was ambivalent about trying the VAD. Progress has been made in incorporating patient preferences in medical decision making, but much more work is needed. To this end, the authors have developed a 5-step framework for incorporating the best features of an evidence-based and preference-based approach. The first step in practicing preference-based medicine is to have an effective meeting of the patient, family members, and appropriate members of the treatment team. Clinicians must carefully clarify the medical evidence concerning benefits and burdens of future treatment. The second step involves sharing information and expertise with the patient and family. The treating physicians should explain treatment options and prognosis with and without the treatment while learning about the patient’s values, priorities, and expectations in light of the medical facts. Patient preferences may be broad in that some may lean toward aggressive interventions to prolong life and others toward naturalism. The third step is to critically evaluate the evidence and identify physician and patient biases that might influence decision making. Unrealistic overly optimistic expectations of prolonged life or acceptance of the likelihood of death have a major impact in patient preferences. The fourth step involves integration of the information from the evidence-based and preference-based approaches and making a recommendation on future care. In the case of the patient with end-stage congenital heart defect, the treating cardiologist evaluated the benefits of a VAD in light of patient and family expectations, goals, and clear understanding of the likely outcome with and without VAD insertion. With input from the VAD and palliative care teams, the cardiologist recommended against a VAD. After discharge to home hospice, the patient continued his heart-failure treatments, hoping to live as well and as long as he could without further invasive interventions. In the fifth step, physician performance is evaluated. All aspects of the decision-making process are examined to ensure that the recommendation of the clinicians incorporated the preferences of patients and families. This case demonstrates that medical decisions regarding future care that allow patients to get the most out of medical interventions are those that integrate the preferences of informed patients and families who understand the clinical implications of the decision.
- 1 April 2012
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 56 (2) , 80-81
Association Between Stroke Center Hospitalization for Acute Ischemic Stroke and Mortality
- 1 April 2012
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 56 (2) , 80-81
Association Between Stroke Center Hospitalization for Acute Ischemic Stroke and Mortality